Observational Study of Ibrutinib Use in CLL
NCT03633045 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70
Last updated 2020-02-10
Summary
IB-RU-SCOPE is a "routine-clinical practice" oriented cohort observational study of ibrutinib efficacy and safety in approx. 70 patients with chronic lymphocytic leukemia in the Russian Federation
Conditions
Sponsors & Collaborators
-
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-09-01
- Primary Completion
- 2021-09-30
- Completion
- 2022-04-30
Countries
- Russia
Study Locations
More Related Trials
-
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01724346 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)
NCT04771507 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT04754035 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression
NCT02863718 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice
NCT04094051 ·Status: UNKNOWN
-
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743 ·Status: RECRUITING ·Phase: PHASE3
-
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
NCT01722487 ·Status: COMPLETED ·Phase: PHASE3
-
Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
NCT02912754 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
NCT02758665 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
NCT02158091 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
MEOI and HRQoL in CLL Patients Treated With BTKis
NCT04938141 ·Status: COMPLETED
-
A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia
NCT04016636 ·Status: COMPLETED
-
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT02437019 ·Status: APPROVED_FOR_MARKETING
-
Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
NCT01862445 ·Status: UNKNOWN
-
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
NCT02910583 ·Status: COMPLETED ·Phase: PHASE2
-
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06378138 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT02556892 ·Status: COMPLETED ·Phase: PHASE1
-
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
NCT02381080 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India
NCT03476655 ·Status: COMPLETED
-
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT03462719 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Combination of Ibrutinib and As2O3 in the Treatment of CLL
NCT02757040 ·Status: UNKNOWN ·Phase: PHASE3
-
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
NCT03980002 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
NCT03190330 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting
NCT03720561 ·Status: COMPLETED
-
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
NCT02514083 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2